Repligen’s stock tumbled 7% after weak earnings guidance sent investors into a panic—especially with Danaher also reporting delayed customer projects and a $100M revenue hit pushed to 2027. The biotech equipment maker, already known for its volatile performance and reliance on big orders, is feeling the squeeze as industry-wide slowdowns ripple through the sector. Despite a brutal 18.8% year-to-date drop, Repligen’s wild swings—16 moves over 5% in a year—suggest this dip might not be the end of the story, though it’s a stark reminder of the risks in this high-volatility space.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
